share_log

Insiders At Mirum Pharmaceuticals Sold US$623k In Stock, Alluding To Potential Weakness

Insiders At Mirum Pharmaceuticals Sold US$623k In Stock, Alluding To Potential Weakness

mirum pharmaceuticals的內部人員以623,000美元的價格出售了股票,暗示着潛在的弱勢。
Simply Wall St ·  08/31 21:32

Quite a few Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insiders sold their shares over the past year, which may be a cause for concern. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, if numerous insiders are selling, shareholders should investigate more.

過去一年裏,不少Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)的內部人士賣出了股票,可能引起擔憂。在分析內部人士的交易時,了解內部人士是否在買入相比於賣出更有參考價值,因爲賣出傳遞出一種模糊的信息。然而,如果有多位內部人士在賣出股票,股東們應該進行更深入的調查。

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

雖然我們不認爲股東應該簡單地跟隨內部交易,但完全忽略內部交易將是愚蠢的。

The Last 12 Months Of Insider Transactions At Mirum Pharmaceuticals

Mirum Pharmaceuticals上市公司近12個月的內部交易

In the last twelve months, the biggest single purchase by an insider was when Chief Financial Officer Eric Bjerkholt bought US$296k worth of shares at a price of US$29.65 per share. We do like to see buying, but this purchase was made at well below the current price of US$43.11. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

過去十二個月裏,Mirum Pharmaceuticals的首席財務官Eric Bjerkholt以每股29.65美元的價格購買了總價值29.6萬美元的股票。我們確實希望看到內部人士購買,但是這次購買的價格遠低於當前的43.11美元。因爲它發生在一個較低的估值時期,它對於我們判斷內部人士是否認爲今天的股價有吸引力並沒有太大的參考價值。

All up, insiders sold more shares in Mirum Pharmaceuticals than they bought, over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

總的來說,Mirum Pharmaceuticals的內部人士在過去一年裏賣出的股票比買入的多。下面的圖表顯示了過去一年內內部人士(公司和個人)的交易情況。如果你想知道究竟是誰以及以多少和何時賣出,只需點擊下面的圖表!

1725111127709
NasdaqGM:MIRM Insider Trading Volume August 31st 2024
納斯達克GM:mirum pharmaceuticals內部交易量2024年8月31日

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

如果您和我一樣,您就不會錯過這個免費的小盤股票列表,這些股票不僅被內部人士購買,而且估值也很有吸引力。

Does Mirum Pharmaceuticals Boast High Insider Ownership?

Mirum Pharmaceuticals是否擁有高內部所有權?

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 1.9% of Mirum Pharmaceuticals shares, worth about US$38m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

許多投資者喜歡查看公司被內部人員持有的股份比例。我認爲,如果內部人員在公司擁有相當數量的股份,這是一個好跡象。內部人員擁有mirum pharmaceuticals股份的1.9%,價值約3800萬美元。這種內部所有權程度很好,但還不足以引人關注。這確實表明了合理程度的一致性。

So What Does This Data Suggest About Mirum Pharmaceuticals Insiders?

那麼,這些數據對Mirum Pharmaceuticals內部人員意味着什麼?

There haven't been any insider transactions in the last three months -- that doesn't mean much. Our analysis of Mirum Pharmaceuticals insider transactions leaves us cautious. But we do like the fact that insiders own a fair chunk of the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. While conducting our analysis, we found that Mirum Pharmaceuticals has 2 warning signs and it would be unwise to ignore them.

在過去三個月裏,沒有任何內部交易——這並不意味着太多。我們對mirum pharmaceuticals內部交易的分析讓我們保持謹慎。但我們喜歡內部人員擁有這家公司相當大比例的股份。因此,這些內部交易可以幫助我們建立有關股票的論點,但了解這家公司面臨的風險也很重要。在進行分析時,我們發現mirum pharmaceuticals有2個警示信號,忽視它們不明智。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論